Recombinant protein vaccine with adjuvant

This page covers all Recombinant protein vaccine with adjuvant drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Influenza hemagglutinin (HA) protein, SARS-CoV-2 spike protein, HPV-16 L1 and HPV-18 L1 capsid proteins.

Targets

Influenza hemagglutinin (HA) protein · SARS-CoV-2 spike protein · HPV-16 L1 and HPV-18 L1 capsid proteins

Marketed (1)

• Licensed seasonal influenza vaccine · Novavax · Immunology / Infectious Disease
  Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.

Phase 3 pipeline (2)

• SARS-CoV-2 rS antigen/Matrix-M Adjuvant · Novavax · Immunology / Infectious Disease
  This vaccine delivers the SARS-CoV-2 spike protein antigen with Matrix-M adjuvant to stimulate immune responses against COVID-19.
• HPV-16/18 L1/AS04 · GlaxoSmithKline · Oncology / Immunology
  This vaccine stimulates the immune system to produce antibodies and cellular immunity against HPV-16 and HPV-18 L1 capsid proteins, preventing infection and cervical cancer development.